Clinical Trials Logo

Pancreatic Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Ductal Adenocarcinoma.

Filter by:

NCT ID: NCT05042128 Active, not recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1/LSTA1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

ASCEND
Start date: April 13, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1/LSTA1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.

NCT ID: NCT05031494 Active, not recruiting - Melanoma Clinical Trials

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Start date: December 8, 2021
Phase: Phase 2
Study type: Interventional

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)

NCT ID: NCT04999761 Recruiting - Colorectal Cancer Clinical Trials

AB122 Platform Study

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

NCT ID: NCT04976634 Recruiting - Clinical trials for Colorectal Neoplasms

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

NCT ID: NCT04975217 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Start date: December 14, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial examines the safety and effects of fecal microbial transplants in treating patients with pancreatic cancer. scheduled for surgery to remove tumors. Fecal microbial transplant contains the normal microbes found in fecal (stool) material. Giving fecal microbial transplant may help control the disease.

NCT ID: NCT04970056 Recruiting - Pancreas Cancer Clinical Trials

Pancreatic Cancer Early Detection Consortium

PRECEDE
Start date: September 18, 2020
Phase:
Study type: Observational

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

NCT ID: NCT04969731 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Start date: September 7, 2021
Phase: Phase 3
Study type: Interventional

PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.

NCT ID: NCT04954378 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer

Start date: January 1, 2010
Phase:
Study type: Observational

Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis

NCT ID: NCT04927780 Recruiting - Pancreatic Cancer Clinical Trials

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

PREOPANC-3
Start date: September 7, 2021
Phase: Phase 3
Study type: Interventional

The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.

NCT ID: NCT04913337 Active, not recruiting - Breast Cancer Clinical Trials

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Start date: June 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies